International journal of toxicology
January 31, 2026
Amir Lotfi, Samantha Sparapani, Mylène Pouliot et al.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a serotonin receptor agonist, in clinical development for the treatment of major depression and other psychiatric disorders. A critical safety concern for serotonergic compounds is their potential to induce seizures, as a severe manifestation of serotonin toxicity. The objective of this study was to evaluate the seizure liability of 5-MeO-DMT in a...
International Journal of Medical Sciences
January 30, 2026
Effect of Virtual Reality-Based Mindfulness Program vs Audio-Guided Mindfulness on Depression, Sleep, and Quality of Life in Dementia Family Caregivers: An Exploratory Randomized Controlled Trial.
Journal of Affective Disorders
January 30, 2026
Yao-Zu Li, Cai-Qun Zhao, Mu-Yan Zuo et al.
To evaluate the efficacy and safety of a multimodal rapid anti-depression therapy that combines esketamine treatment with dexmedetomidine patient-controlled sleep (PCSL) in patients with treatment-resistant depression (TRD). We retrospectively included 233 patients with TRD who received the multimodal treatment. Baseline clinical characteristics were collected. Follow-up assessments were...
Gaceta Médica de Caracas
January 29, 2026
Wachidah Yuniartika
Introduction: Depression among older adults is a multifaceted public health concern influenced by factors such as spousal loss, social isolation, and biological and psychological changes. Mindful yoga therapy, integrating gentle physical movements with mindfulness practices, offers a non-pharmacological approach to improving mental health in this population.
Journal of Psychiatric Research
January 29, 2026
Dandan Luo, Wenjun Dang, Jie Luo et al.
Individuals with autism spectrum disorder (ASD) and their caregivers often face challenges such as emotional distress and stress management, which severely impact their quality of life. Mindfulness-Based Stress Reduction (MBSR) holds potential value in emotional regulation; however, there is a lack of systematic evaluation targeting the ASD population, particularly caregivers. This systematic...
Translational Psychiatry
January 29, 2026
Rafael V Lima Da Cruz, Rêmullo B. G. De Miranda Costa, Gabriel M. De Queiroz et al.
2 citations
Major depressive disorder (MDD) remains a leading cause of disability worldwide, with current treatments limited by delayed onset and low efficacy. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) has shown rapid antidepressant effects in early clinical studies, yet its mechanisms and efficacy remain poorly characterized in established models of depression. Here, we evaluated the...
European journal of anaesthesiology
January 29, 2026
Tiantian Chu, Xiaoling Peng, Keliang Wan et al.
2 citations
Postpartum depression (PPD) is a common complication after childbirth, especially in primiparae. This trial sought to evaluate whether prophylactic administration of esketamine during the perinatal period could prevent PPD in primiparae without predisposition to prenatal depression. A prospective, double-blind, multicentre, randomised controlled trial. Three academic hospitals. Primiparae...
The Journal of ECT
January 29, 2026
Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón et al.
1 citation
This case series describes the combined use of electroconvulsive therapy (ECT) and intranasal esketamine (ESK)-2 rapidly acting, evidence-based options for treatment-resistant depression (TRD). Each can leave residual symptoms or early relapse. Whether concurrent use confers more durable benefit remains unclear. We followed 4 adults (50 to 72 y) with severe TRD who had shown partial or waning...
Psychology and Mental Health Care
January 28, 2026
Kianoush Saberi *
Transition to work requires the female students to be compatible with new environments, situations and people that often lead to depression, stress, anxiety and ambiguity. In order to overcome this issue, the concept of mindfulness delivers mental health and welfare notably in depressive and stressful situation as well as feelings of anxiety and concern. Thus, an endeavor in this paper has been...
Brazilian Journal of Health Review
January 28, 2026
Juliana Chies Galvan, Marina Chies Galvan, Rafael Moreno Ferro de Araújo
Bipolar depression is the most prevalent state throughout the life of the bipolar patient, even so, few studies have focused on the treatment of depression in this population. Between the available medications approved for treatment of bipolar depression, ketamine is an option that must be considered. The purpose of this paper was to review the scientific evidence on the efficacy of using...
Expert Opinion on Therapeutic Targets
January 28, 2026
Gia Han Le, Roger S McIntyre
1 citation
Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...
Journal of Affective Disorders
January 28, 2026
Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al.
3 citations
Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...
International Journal of Innovative Technologies in Social Science
January 28, 2026
Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 27, 2026
Rhea Subba, Surendar Ellappan, Sugato Banerjee et al.
Major depressive disorder (MDD) is a debilitating neuropsychiatric condition that affects individuals worldwide. While neuronal deficits have long been recognized in depression pathogenesis, astroglia are increasingly gaining attention. Astroglia are essential for maintaining brain homeostasis, and regulate neurotransmission, neuroinflammation, and metabolic processes that are disrupted in MDD....
Quality in Sport
January 26, 2026
Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.
Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...
Zenodo (CERN European Organization for Nuclear Research)
January 26, 2026
Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker et al.
preprint
This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analyses, and mechanistic research. A comprehensive literature search across major scientific databases identified empirical studies evaluating psilocybin’s effects on depressive symptomatology, safety, and underlying neurobiological mechanisms....
Emerging Minds Journal for Student Research
January 25, 2026
Rishika Scott, James Smith
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not fully understood. The aim of this systematic review is to determine a stable and effective dosage unit to inform health professionals of the benefits of psilocybin, using peer-reviewed literature and meta-analysis. The review will also compare selective...
The Brown University Psychopharmacology Update
January 24, 2026
Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatient treatment for depression, a randomized trial has found. Patients receiving ketamine also showed no improvement relative to those receiving midazolam on measures of cognition and quality of life. Study results were published online Oct. 22, 2025 in...
Neuroscience & Biobehavioral Reviews
January 24, 2026
Omer A. Syed, Benjamin Tsang, Sean M. Nestor et al.
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in treating depression, there remains a need for consensus on optimal methodologies and standardization of PAT protocols. The objective of this review was to assess the efficacy of PAT in treating depressive symptoms and to systematically examine the...
BJPsych Open
January 23, 2026
Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al.
2 citations
Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...